EDIT Stock Price, Editas Medicine Inc Quote, Chart

Market Summary

USD5.35-0.11

Market Closed

-2.01%

EDIT Stock Price

View Fullscreen

EDIT RSI Chart

EDIT Valuation

Market Cap

437.7M

Price/Earnings (Trailing)

-2.86

Price/Sales (Trailing)

5.6

Price/Free Cashflow

-3.2

EDIT Price/Sales (Trailing)

EDIT Profitability

Return on Equity

-43.89%

Return on Assets

-30.7%

Free Cashflow Yield

-31.28%

EDIT Fundamentals

EDIT Revenue

Revenue (TTM)

78.1M

Rev. Growth (Yr)

818.74%

Rev. Growth (Qtr)

1.0K%

EDIT Earnings

Earnings (TTM)

-153.2M

Earnings Growth (Yr)

68.93%

Earnings Growth (Qtr)

58.08%

Breaking Down EDIT Revenue

Last 7 days

-6.7%

Last 30 days

-26.9%

Last 90 days

-32.1%

Trailing 12 Months

-30.6%

How does EDIT drawdown profile look like?

EDIT Financial Health

Current Ratio

5.39

EDIT Investor Care

Shares Dilution (1Y)

18.62%

Diluted EPS (TTM)

-2.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	22.8M	19.3M	24.6M	78.1M
2022	25.8M	31.8M	25.6M	19.7M
2021	91.5M	81.1M	24.5M	25.5M
2020	24.2M	32.6M	91.6M	90.7M
2019	30.1M	25.0M	14.4M	20.5M
2018	17.0M	21.2M	29.5M	31.9M
2017	5.9M	5.6M	11.0M	13.7M
2016	2.4M	5.7M	5.9M	6.1M
2015	0	0	0	1.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Editas Medicine Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	o'neill gilmore neil	sold	-732,884	9.4172	-77,824	ceo
Mar 04, 2024	mei baisong	sold	-191,425	9.4173	-20,327	svp, chief medical officer
Mar 02, 2024	lucera erick	acquired	-	-	61,266	evp, chief financial officer
Mar 02, 2024	burkly linda	acquired	-	-	39,855	evp, chief scientific officer
Mar 02, 2024	o'neill gilmore neil	acquired	-	-	275,125	ceo
Mar 02, 2024	mei baisong	acquired	-	-	89,815	svp, chief medical officer
Dec 05, 2023	eaton bruce	sold	-1,122	10.8972	-103	evp, cbo and cto
Nov 14, 2023	eaton bruce	sold	-5,705	8.2096	-695	evp, cbo and cto
Nov 07, 2023	eaton bruce	sold	-1,167	8.4	-139	evp, cbo and cto
Sep 06, 2023	eaton bruce	sold	-908	8.82	-103	evp, cbo and cto

Which funds bought or sold EDIT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-564	2,968	-%
Apr 23, 2024	WASHINGTON TRUST Co	unchanged	-	-1,197	3,280	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-63.82	-58,000	21,000	-%
Apr 23, 2024	Morton Brown Family Wealth, LLC	unchanged	-	-176	482	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	101,567	441,577	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	35.81	-13,749	2,610,520	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	added	6.16	-135,540	473,982	-%
Apr 22, 2024	America First Investment Advisors, LLC	new	-	1,113	1,113	-%
Apr 19, 2024	Westside Investment Management, Inc.	unchanged	-	-5,043	13,699	-%
Apr 19, 2024	Financial Perspectives, Inc	unchanged	-	-16.00	45.00	-%

Are Funds Buying or Selling EDIT?

Are funds buying EDIT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EDIT

No. of Funds

Unveiling Editas Medicine Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	state street corp	10.71%	8,760,151	SC 13G/A
Feb 14, 2024	deep track capital, lp	6.70%	5,473,086	SC 13G/A
Feb 13, 2024	vanguard group inc	10.36%	8,461,701	SC 13G/A
Jan 24, 2024	blackrock inc.	9.6%	7,838,969	SC 13G/A
Jan 10, 2024	state street corp	6.21%	5,069,543	SC 13G/A
Aug 04, 2023	deep track capital, lp	5.51%	4,493,416	SC 13G
Feb 09, 2023	vanguard group inc	10.00%	6,873,123	SC 13G/A
Feb 03, 2023	state street corp	13.41%	9,222,236	SC 13G/A
Jan 26, 2023	blackrock inc.	10.7%	7,338,742	SC 13G/A
Jan 20, 2023	blackrock inc.	10.7%	7,338,742	SC 13G/A

Recent SEC filings of Editas Medicine Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	DEFA14A	DEFA14A
Apr 16, 2024	DEF 14A	DEF 14A
Apr 10, 2024	SC 13G/A	Major Ownership Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent
Feb 28, 2024	S-8	Employee Benefits Plan
Feb 28, 2024	S-3ASR	S-3ASR

Peers (Alternatives to Editas Medicine Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-12.04%	-45.12%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Editas Medicine Inc News

Latest updates

Editas Medicine Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	1025.4%	60.00	5.00	3.00	10.00	7.00	0.00	6.00	7.00	12.00	6.00	0.00	6.00	11.00	63.00	11.00	6.00	12.00	4.00	2.00	2.00	6.00
Operating Expenses	51.4%	84.00	55.00	47.00	61.00	70.00	58.00	61.00	58.00	54.00	45.00	56.00	63.00	77.00	54.00	42.00	52.00	52.00	38.00	38.00	33.00	32.00
S&GA Expenses	-3.5%	14.00	15.00	17.00	23.00	18.00	16.00	17.00	20.00	17.00	16.00	22.00	21.00	16.00	20.00	14.00	18.00	17.00	16.00	14.00	17.00	13.00
R&D Expenses	71.7%	70.00	41.00	30.00	38.00	52.00	41.00	44.00	38.00	38.00	29.00	34.00	42.00	62.00	34.00	28.00	35.00	35.00	23.00	24.00	16.00	19.00
Net Income	58.1%	-18.87	-45.02	-40.29	-49.04	-60.74	-55.73	-53.45	-50.51	-41.44	-39.08	-55.26	-56.73	-62.50	8.00	-23.57	-37.72	-37.77	-32.94	-33.79	-29.25	-25.05
Net Income Margin	75.3%	-1.96*	-7.93*	-10.65*	-9.61*	-11.18*	-7.84*	-5.80*	-7.22*	-7.54*	-8.72*	-2.05*	-1.48*	-	-	-	-	-	-	-	-	-
Free Cashflow	34.0%	-23.55	-35.70	-40.04	-37.61	-42.90	-48.62	-38.48	-51.47	-37.43	-43.13	-41.66	-49.56	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.1%	499	505	542	464	514	531	581	623	677	717	756	780	573	597	655	467	509	372	356	379	420
Current Assets	-5.0%	341	359	441	324	357	427	461	497	507	568	616	632	419	507	610	425	464	339	324	347	375
Cash Equivalents	49.8%	124	83.00	221	129	142	215	173	215	207	264	342	359	144	283	490	235	240	106	212	160	136
Net PPE	4.1%	12.00	12.00	13.00	13.00	16.00	15.00	16.00	17.00	17.00	16.00	15.00	14.00	14.00	14.00	13.00	12.00	11.00	10.00	9.00	8.00	40.00
Liabilities	4.1%	150	144	142	147	154	116	115	110	124	130	143	142	179	156	229	232	246	162	163	162	184
Current Liabilities	7.9%	63.00	59.00	55.00	57.00	60.00	42.00	36.00	37.00	47.00	51.00	66.00	64.00	58.00	55.00	68.00	69.00	60.00	67.00	73.00	41.00	36.00
Shareholder's Equity	-3.2%	349	360	400	317	361	415	465	513	554	587	613	638	394	441	427	235	262	210	193	217	236
Retained Earnings	1.0%	-1,200	-1,212	-1,200	-1,127	-1,078	-1,017	-961	-908	-857	-816	-777	-721	-665	-602	-610	-586	-549	-511	-478	-444	-416
Additional Paid-In Capital	0.4%	1,580	1,574	1,570	1,447	1,442	1,436	1,430	1,423	1,412	1,403	1,391	1,360	1,059	1,044	1,037	821	812	721	672	662	652
Shares Outstanding	0.1%	82.00	82.00	82.00	69.00	69.00	69.00	69.00	68.00	68.00	68.00	68.00	66.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	671	-	-	-	634	-	-	-	1,147	-	-	-	1,840	-	-	-	1,222	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	37.3%	-22,240	-35,459	-38,711	-35,768	-42,273	-48,004	-37,845	-49,227	-34,582	-40,785	-38,957	-49,479	-40,100	-54,801	-30,856	-54,086	41,024	-26,884	-25,806	-29,003	1,327
Share Based Compensation	13.0%	5,345	4,731	5,215	4,507	5,364	5,881	6,618	11,431	7,657	10,012	13,526	12,204	5,673	5,846	5,417	6,220	6,336	6,559	6,493	7,855	6,347
Cashflow From Investing	161.1%	62,840	-102,820	12,982	23,267	-27,528	89,227	-4,002	56,371	-22,840	-39,661	4,791	3,244	-108,894	-152,265	74,173	46,464	7,818	-122,302	76,110	50,626	-8,604
Cashflow From Financing	-	514	-	-	-	619	80.00	367	218	1,057	2,496	17,082	261,471	9,100	822	211,153	3,047	84,569	43,353	2,369	1,533	30,352

EDIT Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Collaboration and other research and development revenues	$ 78,123	$ 19,712	$ 25,544
Revenue type	Service [Member]	Service [Member]	Service [Member]
Operating expenses:
Research and development	$ 177,651	$ 174,958	$ 142,507
General and administrative	69,653	70,704	76,183
Total operating expenses	247,304	245,662	218,690
Operating loss	(169,181)	(225,950)	(193,146)
Other income, net:
Other income, net	(1,604)	0	37
Interest income, net	17,566	5,518	607
Total other income, net	15,962	5,518	644
Net loss	$ (153,219)	$ (220,432)	$ (192,502)
Net loss per share, basic (in dollars per share)	$ (2.02)	$ (3.21)	$ (2.85)
Net loss per share, diluted (in dollars per share)	$ (2.02)	$ (3.21)	$ (2.85)
Weighted-average common shares outstanding, basic (in shares)	75,965,633	68,664,822	67,619,388
Weighted-average common shares outstanding, diluted (in shares)	75,965,633	68,664,822	67,619,388

EDIT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 123,652	$ 141,522
Marketable securities	199,459	202,752
Accounts receivable	10,187	5,145
Prepaid expenses and other current assets	7,531	7,335
Total current assets	340,829	356,754
Marketable securities	104,024	93,097
Property and equipment, net	12,032	15,569
Right-of-use assets	33,680	43,648
Restricted cash and other non-current assets	8,588	5,253
Total assets	499,153	514,321
Current liabilities:
Accounts payable	8,269	9,511
Accrued expenses	34,563	31,296
Deferred revenue, current	8,221	8,221
Operating lease liabilities	12,164	11,082
Total current liabilities	63,217	60,110
Operating lease liabilities, net of current portion	24,372	32,864
Deferred revenue, net of current portion	60,667	60,667
Other non-current liabilities	1,800	0
Total liabilities	150,056	153,641
Stockholders’ equity
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 81,767,263 and 68,847,382 shares issued, and 81,767,263 and 68,847,382 shares outstanding at December 31, 2023 and December 31, 2022, respectively	8	7
Additional paid-in capital	1,580,241	1,442,405
Accumulated other comprehensive income (loss)	198	(3,601)
Accumulated deficit	(1,231,350)	(1,078,131)
Total stockholders’ equity	349,097	360,680
Total liabilities and stockholders’ equity	$ 499,153	$ 514,321

About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

CEO	Dr. Gilmore O'Neill
WEBSITE	editasmedicine.com
INDUSTRY	Biotechnology
EMPLOYEES	226

Editas Medicine Inc Frequently Asked Questions

What is the ticker symbol for Editas Medicine Inc? What does EDIT stand for in stocks?

EDIT is the stock ticker symbol of Editas Medicine Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Editas Medicine Inc (EDIT)?

As of Tue Apr 23 2024, market cap of Editas Medicine Inc is 446.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EDIT stock?

You can check EDIT's fair value in chart for subscribers.

What is the fair value of EDIT stock?

You can check EDIT's fair value in chart for subscribers. The fair value of Editas Medicine Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Editas Medicine Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EDIT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Editas Medicine Inc a good stock to buy?

The fair value guage provides a quick view whether EDIT is over valued or under valued. Whether Editas Medicine Inc is cheap or expensive depends on the assumptions which impact Editas Medicine Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EDIT.

What is Editas Medicine Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, EDIT's PE ratio (Price to Earnings) is -2.92 and Price to Sales (PS) ratio is 5.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EDIT PE ratio will change depending on the future growth rate expectations of investors.